A number of labs have said that not only are they able to fulfill all current PCR test requests, but that they are operating at below capacity for these tests.
A lack of specificity in CMS guidelines combined with increased FDA scrutiny of LDTs could make it more difficult for labs to make changes to existing assays.
A number of labs and informatics firms are using test data to help guide the response to the virus in a spirit similar to that of initiatives like Lab 2.0.
Total revenues fell to $1.82 billion from $1.89 billion in Q1 2019 as the company saw test volumes drop significantly in the face of the COVID-19 pandemic.
With clinical labs suffering large drops in volumes as patients stay away from draw centers, remote sampling could provide a way to offer routine testing.
Quest's management, including CEO Steve Rusckowski, will take temporary pay cuts, while rank-and-file employees may be furloughed or have their overtime reduced.
The tool integrates data from more than 20,000 testing locations across the country and is intended to help providers plan their response to the pandemic.
The registry will compile data from LabCorp's SARS-CoV-2 testing with longitudinal medical data to help clinicians better manage and treat the disease.
This week Quest Diagnostics said it saw declines of more than 40 percent while other industry observers reported drops of as much as 90 percent for some labs.
The firm believes that its molecular assay for the laboratory will help ease some of the supply chain issues hampering test rollout during the pandemic.
